Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Horien Biochemical Technology Co EV-to-EBITDA?
Horien Biochemical Technology CoROCO:7814 +0.18%28 EV-to-EBITDA is 70.28 as of Sep. 21, 2026, which is 15% below its 10-year median of 83.15. GuruFocus rates ROCO:7814 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 430 Biotechnology companies, Horien Biochemical Technology Co ranks worse than 88.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Horien Biochemical Technology Co's enterprise value is NT$1,076.4 Mil.
Horien Biochemical Technology Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$15.3 Mil. Therefore, Horien Biochemical Technology Co's EV-to-EBITDA for today is 70.28.
The historical rank and industry rank for Horien Biochemical Technology Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7814'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 38.36 Med: 83.15 Max: 416.99
Current: 70.28
During the past 4 years, the highest EV-to-EBITDA of Horien Biochemical Technology Co was 416.99. The lowest was 38.36. And the median was 83.15.
ROCO:7814's EV-to-EBITDA is ranked worse than 88.14% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs ROCO:7814: 70.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Horien Biochemical Technology Co (ROCO:7814) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Horien Biochemical Technology Co's PE Ratio (TTM) for today is calculated as:
Horien Biochemical Technology Co's share price for today is NT$28.55.
Horien Biochemical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.141.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co EV-to-EBITDA Chart
ROCO:7814 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Horien Biochemical Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Horien Biochemical Technology Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Horien Biochemical Technology Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Horien Biochemical Technology Co's EV-to-EBITDA falls into.
Horien Biochemical Technology Co's current Enterprise Value is NT$1,076.4 Mil.
Horien Biochemical Technology Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$15.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co (ROCO:7814) has a EV-to-EBITDA of 70.28 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Horien Biochemical Technology Co. This is 15% below median its historical median of 83.15. Over the past decade, Horien Biochemical Technology Co's EV-to-EBITDA has ranged from 38.36 to 416.99. According to the industry distribution chart, Horien Biochemical Technology Co ranks #379 out of 430 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Horien Biochemical Technology Co's EV-to-EBITDA too high?
Horien Biochemical Technology Co's current EV-to-EBITDA of 70.28 is 15% below median its 10-year median of 83.15. Over the past 10 years, this metric has ranged from a low of 38.36 to a high of 416.99. The Biotechnology industry median EV-to-EBITDA is 13.02. Horien Biochemical Technology Co's value of 70.28 is 440% above this industry median. Based on the distribution chart, Horien Biochemical Technology Co ranks #379 out of 430 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Horien Biochemical Technology Co has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Horien Biochemical Technology Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Horien Biochemical Technology Co ranks #379 out of 430 companies for EV-to-EBITDA. This places Horien Biochemical Technology Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Horien Biochemical Technology Co's value of 70.28 is 440% above this benchmark. Historically, Horien Biochemical Technology Co's own EV-to-EBITDA has ranged from 38.36 to 416.99 over the past decade. While the company's 10-year median is 83.15 vs. the industry median of 13.02, Horien Biochemical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Horien Biochemical Technology Co's current EV-to-EBITDA of 70.28 is 440% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Horien Biochemical Technology Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Horien Biochemical Technology Co's current EV-to-EBITDA is 70.28, which is 15% below median its own 10-year median of 83.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Horien Biochemical Technology Co stock overvalued right now?
Horien Biochemical Technology Co (ROCO:7814) has a current EV-to-EBITDA of 70.28. The current EV-to-EBITDA is 70.28, which is 15% below median its 10-year median of 83.15 and 440% above the Biotechnology industry median of 13.02. Horien Biochemical Technology Co's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Horien Biochemical Technology Co (ROCO:7814), the current EV-to-EBITDA is 70.28 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Horien Biochemical Technology Co Ltd is engaged in the research and development of cosmetic raw materials and medical devices and facilities. The products of the company include Gen-Nusis, skin repairment ingredients, PeptioMax, the latest cosmetic raw material, Lifkin, and other substitutes used in dentistry and general surgery.
28GF Score
Get the complete analysis for ROCO:7814
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7814 has been successfully added to your 
